Department of Obstetrics and Gynecology, Division of Family Planning Services and Research, Stanford University School of Medicine, Stanford, CA.
Department of Obstetrics and Gynecology, Division of Family Planning Services and Research, Stanford University School of Medicine, Stanford, CA.
Am J Obstet Gynecol. 2019 Feb;220(2):177.e1-177.e7. doi: 10.1016/j.ajog.2018.11.1085. Epub 2018 Nov 13.
A major barrier to intrauterine device use is fear of pain during insertion. Trials exploring analgesic interventions for intrauterine device insertion have yielded mixed results, and no standardized pain management guidelines currently exist for this procedure. In an abortion-related study, self-administered lidocaine gel over a prolonged time interval showed promise as a method of pain control.
OBJECTIVE(S): The objective of the study was to assess pain control with intrauterine device insertion after patient-administered lidocaine gel compared with placebo.
We conducted a randomized, blinded trial of women undergoing levonorgestrel or copper intrauterine device insertion in an outpatient gynecology clinic between July 2016 and April 2017. Participants self-administered either 20 mL of 2% lidocaine gel or placebo gel vaginally at least 15 minutes prior to intrauterine device insertion. No other analgesics were administered. The primary outcome was pain during intrauterine device insertion, measured on a 100-mm visual analog scale (0 being no pain and 100 being worst pain imaginable). Secondary outcomes included anticipated and baseline pain and pain with speculum insertion and tenaculum placement. In a postprocedure questionnaire, participants reported acceptability of vaginal gel and willingness to wait for pain control. Median values were assessed because of the nonnormal distribution of visual analog scale scores using the Mann-Whitney U test. Predictors of intrauterine device insertion pain were assessed using a multiple linear regression.
In total, 220 women were randomized and 215 were included in analysis (108 in lidocaine gel, 107 in placebo gel groups). Median (range) time from gel administration to speculum insertion was 21 (14-74) and 20 (12-43) minutes in the lidocaine and placebo groups, respectively (P = .13). The median pain scores during intrauterine device insertion were not significantly different: 65 (1-99) mm in the lidocaine group and 59 (5-100) mm in the placebo group (P = .09). Among secondary outcome time points, only median pain scores at speculum insertion were significantly different between the lidocaine and placebo groups (7 [0-81] mm vs 11 [0-80] mm, respectively; P = .046). Anticipated pain and menstrual pain were both predictors of pain with intrauterine device insertion. The majority of women in both groups found the amount of vaginal leakage following gel insertion to be acceptable (>80%). Ninety-two percent of participants (n = 194) stated they would be willing to wait before intrauterine device placement for a potential analgesic effect.
Self-administered lidocaine gel at least 15 minutes before intrauterine device insertion does not appear to reduce pain compared with placebo but may help with speculum insertion. We found that women are willing to extend visit time to gain pain control. Self-administration of local anesthetic is acceptable to patients and should be considered in future research.
宫内节育器使用的主要障碍是担心插入过程中的疼痛。探索宫内节育器插入时使用镇痛干预措施的试验结果喜忧参半,目前针对该手术还没有标准化的疼痛管理指南。在一项与堕胎相关的研究中,自行使用利多卡因凝胶持续较长时间间隔显示出控制疼痛的潜力。
本研究旨在评估与安慰剂相比,患者自行使用利多卡因凝胶后宫内节育器插入时的疼痛控制情况。
我们在 2016 年 7 月至 2017 年 4 月期间,对在门诊妇科诊所进行左炔诺孕酮或铜宫内节育器插入的女性进行了一项随机、双盲试验。参与者在宫内节育器插入前至少 15 分钟自行阴道内使用 20 毫升 2%的利多卡因凝胶或安慰剂凝胶。没有给予其他镇痛药。主要结局是 100mm 视觉模拟量表(0 表示无痛,100 表示可想象的最痛)评估的宫内节育器插入时的疼痛。次要结局包括预期和基线疼痛以及阴道镜检查和宫颈钳放置时的疼痛。在术后问卷中,参与者报告了阴道凝胶的可接受性以及对疼痛控制的等待意愿。由于视觉模拟量表评分的非正态分布,使用 Mann-Whitney U 检验评估中位数。使用多元线性回归评估宫内节育器插入疼痛的预测因素。
共有 220 名女性被随机分配,215 名女性纳入分析(利多卡因凝胶组 108 名,安慰剂凝胶组 107 名)。从凝胶给药到阴道镜检查的中位(范围)时间分别为利多卡因组 21(14-74)分钟和安慰剂组 20(12-43)分钟(P=0.13)。宫内节育器插入时的中位疼痛评分无显著差异:利多卡因组 65(1-99)mm,安慰剂组 59(5-100)mm(P=0.09)。在次要结局时间点中,只有阴道镜检查时的中位疼痛评分在利多卡因组和安慰剂组之间有显著差异(分别为 7[0-81]mm 和 11[0-80]mm;P=0.046)。预期疼痛和月经痛均为宫内节育器插入时疼痛的预测因素。两组中大多数女性都认为凝胶插入后阴道漏液量可以接受(>80%)。92%的参与者(n=194)表示愿意在放置宫内节育器前等待一段时间,以获得潜在的镇痛效果。
与安慰剂相比,在宫内节育器插入前至少 15 分钟自行使用利多卡因凝胶似乎并不能减轻疼痛,但可能有助于阴道镜检查。我们发现,女性愿意延长就诊时间以获得疼痛控制。局部麻醉的自我管理可被患者接受,应在未来的研究中考虑。